Scientists reprogram Patient's own cells to hunt deadly cancers
NCT ID NCT03190941
Summary
This trial is testing a new type of gene therapy for people with advanced pancreatic, colon, and other cancers that have a specific genetic change called KRAS G12V. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer cells, and then infuse them back into the patient. The main goals are to see if this treatment is safe and if it can shrink tumors in patients who have few other treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.